![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach:
Dokumententyp
| Veröffentlichungsdatum
Springe zu: Zeitschriftenartikel
Anzahl der Publikationen: 2
Zeitschriftenartikel
Pretzsch, Elise; Peschel, Christiane A.; Rokavec, Matjaz; Torlot, Lucien; Li, Pan; Hermeking, Heiko 
ORCID: https://orcid.org/0000-0001-6586-4406; Werner, Jens; Klauschen, Frederick ORCID: https://orcid.org/0000-0002-9131-2389; Neumann, Jens; Jung, Andreas ORCID: https://orcid.org/0000-0001-5270-9108 und Kumbrink, Jörg ORCID: https://orcid.org/0000-0003-4633-4105
(Mai 2025):
Five-Gene Expression Signature Associated With Acquired FOLFIRI Resistance and Survival in Metastatic Colorectal Cancer.
In: Laboratory Investigation, Bd. 105, Nr. 5, 104107
[PDF, 1MB]
ORCID: https://orcid.org/0000-0001-6586-4406; Werner, Jens; Klauschen, Frederick ORCID: https://orcid.org/0000-0002-9131-2389; Neumann, Jens; Jung, Andreas ORCID: https://orcid.org/0000-0001-5270-9108 und Kumbrink, Jörg ORCID: https://orcid.org/0000-0003-4633-4105
(Mai 2025):
Five-Gene Expression Signature Associated With Acquired FOLFIRI Resistance and Survival in Metastatic Colorectal Cancer.
In: Laboratory Investigation, Bd. 105, Nr. 5, 104107
[PDF, 1MB]
Torlot, Lucien; Jarzab, Anna; Albert, Johanna; Pok-Udvari, Agnes; Stahler, Arndt; Holch, Julian Walter; Gerlinger, Marco; Heinemann, Volker; Klauschen, Frederick; Kirchner, Thomas; Kumbrink, Jörg; Küster, Bernhard und Jung, Andreas ORCID: https://orcid.org/0000-0001-5270-9108
(2022):
Proteomics uncover EPHA2 as a potential novel therapeutic target in colorectal cancer cell lines with acquired cetuximab resistance.
In: Journal of Cancer Research and Clinical Oncology, Bd. 149, Nr. 2: S. 669-682
[PDF, 2MB]
ORCID: https://orcid.org/0000-0001-5270-9108
(2022):
Proteomics uncover EPHA2 as a potential novel therapeutic target in colorectal cancer cell lines with acquired cetuximab resistance.
In: Journal of Cancer Research and Clinical Oncology, Bd. 149, Nr. 2: S. 669-682
[PDF, 2MB]